Logo of jester cap with thought bubble.

Image source: The Motley Fool.

DATE

Thursday, April 30, 2026 at 5 p.m. ET

CALL PARTICIPANTS

  • President and Chief Executive Officer — Joseph Papa
  • Executive Vice President and Chief Financial Officer — Richard Lindahl

TAKEAWAYS

  • Total Revenue -- $156 million, above the high end of prior guidance of $135 million to $155 million, indicating higher-than-expected sales.
  • Adjusted EBITDA -- $36 million with a 23% margin, including non-cash stock compensation in line with peer practices starting this quarter.
  • Adjusted Gross Margin -- 52%, underscoring the impact of high fixed costs within Emergent BioSolutions (EBS +5.95%) operations.
  • Operating Expenses -- $57 million, a $10 million decline year over year, reflecting ongoing cost discipline.
  • R&D Spending -- Down approximately one-third from the prior year, showing a reduction in development spend.
  • Liquidity -- Cash improved by $11 million versus the prior year to $160 million, with total liquidity at $260 million.
  • Net Debt Reduction -- Lowered by $122 million or roughly 22% compared to the first quarter of 2025.
  • Debt Refinancing -- April 2026 refinancing decreased term loan debt by $100 million, established a new $75 million delayed draw term loan, and extended maturities to 2031.
  • Share Repurchases -- $9 million repurchased in the quarter; $34 million total since program inception in 2025; $46.5 million in authorized repurchase capacity remains through March 2027.
  • Multi-Product Government Deal -- Signed a $140 million multiproduct agreement with the government of Canada.
  • Additional Government Contracts -- Secured a $54 million legal award with ASPR and a $21.5 million BioThrax delivery order to the Department of War.
  • MCM International Revenue -- International markets accounted for 37% of MCM segment revenue, versus historic “mid-teens” exposure, reflecting significant expansion.
  • Naloxone Franchise Growth -- Launched NARCAN Nasal Spray carrying case and multipack, both performing well initially.
  • Upcoming Payment Obligation -- $50.4 million contingent consideration to Ridgeback Bio to be paid in the second quarter, tied to progress on the Ebanga program and the BARDA contract.
  • Adjusted EBITDA Guidance -- Updated for stock compensation add-back; full year expectation is $155 million to $175 million.
  • Full-Year Revenue Guidance -- Maintained at $720 million to $760 million; Q2 revenue expected in the $170 million to $185 million range.
  • Adjusted Gross Margin Guidance -- Projected at 45%-47% for the full year, reflecting anticipated product mix and pricing.
  • MCM Margins -- Management stated international MCM sales generate higher margins than domestic due to most-favored nation pricing agreements with the U.S. government.
  • Canton Facility -- Expansion underway with Substipharm Biologics partnership for Japanese encephalitis vaccine manufacturing and U.S. distribution following FDA approval.
  • Second Strategic Manufacturing Partnership -- Announced new collaboration with SAB Biotherapeutics for a type 1 diabetes candidate, led by the Winnipeg team.

Need a quote from a Motley Fool analyst? Email [email protected]

RISKS

  • Richard Lindahl reported, "We previously disclosed that $50.4 million of contingent consideration could be owed to Ridgeback Bio in the second quarter of this year," which will result in a significant cash outflow tied to the Ebanga program if contract progress continues as expected.
  • Richard Lindahl noted, "on our last earnings call, we pointed out that our 2025 results benefited from a large international order that we do not currently expect to repeat in 2026," referencing the $60 million revenue and $50 million adjusted EBITDA contribution, potentially skewing year-over-year comparisons.

SUMMARY

Emergent BioSolutions demonstrated revenue and profitability above previously issued guidance, supported by operational cost reductions, disciplined R&D spending, and a major jump in the international contribution of MCM segment sales. Debt obligations were meaningfully reduced, and recently completed refinancing measures provided both lower interest costs and a multi-year extension of loan maturities, improving financial flexibility. Strategic government contracts and product launches, including the Canadian multiproduct agreement and new NARCAN configurations, signaled management’s focus on diverse revenue streams and innovation. Substantial authorized share repurchase capacity remains in place, reflecting ongoing capital returns, with incremental partnerships pointing to a growing external footprint.

  • The $9 million in share buybacks during the quarter consumed part of a remaining $46.5 million repurchase authorization available through March 2027.
  • International MCM sales climbed markedly, now representing 37% of the segment, compared to prior year levels reportedly at 34%, and a historic average in the “mid-teens.”
  • Guidance for adjusted EBITDA was raised following a change in methodology to include non-cash stock compensation.
  • Facility expansion and strategic manufacturing partnerships, such as with Substipharm Biologics and SAB Biotherapeutics, positioned the company for both new product channels and contract manufacturing growth.

INDUSTRY GLOSSARY

  • MCM (Medical Countermeasures): Products and technologies developed to address and mitigate public health threats, including bioterrorism, pandemics, and chemical or nuclear incidents.
  • ASPR: Assistant Secretary for Preparedness and Response, a division of the U.S. Department of Health and Human Services responsible for preparing for and responding to public health emergencies.
  • BIO-THRAX: Emergent's proprietary anthrax vaccine, indicated for immunization against anthrax disease.
  • BARD A: Biomedical Advanced Research and Development Authority, a U.S. government agency that supports development and procurement of medical countermeasures.

Full Conference Call Transcript

Joe Papa, President and Chief Executive Officer, who will provide an update on the company's leadership in public health preparedness, business performance and key highlights. Rich Lindahl, EVP and Chief Financial Officer, will then review the first quarter 2026 financial results and provide an update on full year 2026 guidance. Joe will conclude with a discussion of the company's key catalysts for growth, followed by a question-and-answer session. Finally, for the benefit of those who may be listening to the replay of this webcast, this call was held and recorded on April 30, 2026. Since that time, Emergent may have made announcements related to topics discussed during today's call.

With that, I would now like to turn the call over to Joe Poppa. Joe?

Joseph Papa: Thank you, Frank, and good afternoon, everyone. Welcome to our first quarter 2026 earnings call. This is Joe Popa, and I'm joined today by Rich Lindahl, our Chief Financial Officer. Let's turn to Slide 5. Our aspiration at Emergent is to be the leader in solving public health threats around the world. Over the last 25 years, we have built what we believe is the most diverse biodefense product portfolio in the world. Our medical countermeasures address anthrax, smallpox, mpox, Ebola, Botulism and complications from smallpox vaccination, alongside the leading branded naloxone franchise with our NARCAN Nasal Spray, which has a decade of trusted brand leadership.

We believe in our unique position within the industry to demonstrate just how public-private partnerships are critical to national security. Turning to Slide 6. Since implementing our multiyear transformation plan in 2024, we have stabilized and rightsized the company in order to provide Emergent with a strong foundation for future growth. 2026 marks a pivotal year of our transformation as we invest in high-growth opportunities. I'm pleased to note that this process is now well underway. We are focusing on segment revenue growth and improved operating performance. We are generating strong cash flow for continued investment in internal R&D and quality capabilities.

We have identified product acquisition opportunities that address unmet medical needs and have the potential for sustainable long-term revenue growth. Debt reduction will remain a priority for us. In 2025, we reduced our net debt levels by approximately 22%, and we have planned for further improvement on our balance sheet and credit ratings. Collectively, these activities are about putting in place the foundations for creating sustainable long-term value creation. Let's move to Slide 8, we'll take a look at our first quarter highlights. Thanks to the great efforts of our Emergent team our first quarter results are evident in both our top and bottom-line performance.

We reported first quarter revenue of $156 million, which exceeded the high end of our guidance range and was ahead of internal expectations. Adjusted EBITDA came in at $36 million, also above our internal expectations, representing a 23% margin. It's driven by continued efforts to deliver a lean and operationally efficient customer-centric business model. For example, net working capital improved by over $100 million since Q1 2025. We improved our cash balance by $11 million versus the prior year to $160 million, and our total liquidity increased to $260 million. Our strong cash position enabled the repayment of $110 million in debt last year. On the capital allocation side, we continue to create value.

In April, we announced the refinancing of our prior term loan, which enabled us to secure a more favorable interest rate. We also amended our revolver to $50 million and established a new delayed draw term loan facility for $75 million. We also continued our share repurchase program, buying back $9 million in shares in the first quarter. Since the start of the share repurchase program in 2025, Emergent has repurchased approximately $34 million of shares. Turning to our business performance. Overall, MCM performed very well, reflecting increased global demand and strategic diversification in our international markets, which now represent 37% of our total MCM revenue. We received four contracted product orders in the quarter.

With respect to the naloxone business, we continue to maintain the share leadership. We command a competitive pricing strategy and recently launched our newest product offering, the NARCAN Nasal Spray carrying case and a multipack configuration, both of which are already performing very well in the first month of launch. We believe on Slide 9, the world is an increasingly dangerous place and public health preparedness in the face of potential threats is critical. We are proud of our long-standing partnership with the government of Canada. And in Q1, we announced a $140 million multiproduct agreement. We also executed $54 million legal award with ASPR and approximately $21.5 million delivery order to supply BioThrax to the Department of War.

Our MCM business represents an important driver of our future growth. And with the added flexibility from our recent financing, we see multiple opportunities to acquire high-growth and complementary products to our MCM portfolio. Our mission on Slide 10 to protect to save lives is answered every day with the work we do to drive access, awareness and availability of life-saving naloxone. We are in lockstep with U.S. public interest customers, the Canadian health officials, retail customers and all the communities in need. We're keeping pulse on the staggering overdose death rates and ensuring our best efforts to help combat the thousands of lives lost each month.

We believe over-the-counter access to NARCAN should be more publicly accepted and normalized, just as other life-saving emergency tools are like defibrillators or fire extinguisher for that matter. Just in the news this week, this national intention on opioid settlement funds of over $50 billion, which supports state, local municipalities, tribes and other entities to help turn the tide in the detrimental effects of the opioid crisis. The produced settlement alone released over $5 billion for the state for education and naloxone purchase. There's a tremendous amount of work left to be done to expand access and awareness to naloxone and to ultimately bring the number of overdose deaths down to zero.

Federal state programs also continue to support naloxone funding and services through the SOR and substance use block grants. We just announced a new awareness effort with naloxone, NARCAN for professional baseball player, Davis Schneider. Davis Schneider shares his personal story in his late brother's honor. Our goal is to raise the awareness of NARCAN and help save lives from opioid poisoning, so no more families feel the same heartbreak. Additionally, we recently announced a partnership with British Columbia to supply NARCAN Nasal Spray for the province's take-home naloxone program. This order called an additional investment of CAD 18 million by the government of British Columbia.

In the U.S., the U.S. public interest channel performed in line with our expectations for the quarter. U.S. FDA approved our NARCAN Nasal Spray carrying case and multi-pack options, delivering on our promise to offer new line extensions to patients and customers. We will continue to engage the public across the country, especially in college campuses with our ready-to-rescue campaign to help drive adoption where young adults made the efforts. Since 2016, Emergent has delivered more than 100 million doses of NARCAN Nasal Spray to people, communities and businesses across the U.S. and Canada to help save lives for opioid poisonings.

On Slide 11, we are pleased to share that part of our durable and sustainable footprint we are now expanding our Canton manufacturing site in Massachusetts. Our new strategic partnership with Substipharm Biologics enables us to restart the manufacturing of the Canton facility to support the Japanese encephalitis vaccine. Emergent entered into a U.S. distribution agreement with Substipharm to support the product opportunity with the U.S. government following U.S. FDA approval. This opportunity establishes our new approach to external manufacturing partnerships, moving beyond a fee-for-service CDMO approach to one that allows us to share the product's potential success. In addition, just yesterday, we announced a second strategic manufacturing partnership with SAB Biotherapeutics to advance their type 1 diabetes autoimmune candidate.

This work will be led by our Winnipeg team. We're excited for the ability to partner with such a dynamic company. Let's hear from Rich, who will run through our financial results. Rich?

Richard Lindahl: Thank you, Joe, and good afternoon, everyone. Thank you for joining our call today. We started fiscal year 2026 with a strong first quarter with revenue exceeding the top end of our guidance. We've also advanced key strategic priorities and improved our cash and liquidity position versus the prior year. Execution of our 2026 turnaround plan is well underway as we work toward our near-term financial and operational goals, building on the stabilization and rightsizing actions completed over the last two years. We also expect the refinancing announced two weeks ago to provide strategically important balance sheet flexibility, lowering interest costs, extending maturities and adding access to incremental capital to support both operational execution and our longer-term growth initiatives.

Turning to Slide 13. Our first quarter results were in line with our expectations and reflect continued progress on execution. Total revenue for the first quarter of 2026 was $156 million, which came in above the high end of our prior Q1 revenue guidance of $135 million to $155 million. As a reminder, on our last earnings call, we pointed out that our 2025 results benefited from a large international order that we do not currently expect to repeat in 2026. That order contributed approximately $60 million of revenue and $50 million of adjusted EBITDA to our first quarter 2025 results and significantly influences the year-over-year comparisons of these metrics.

Beginning in 2026, we are adding back non-cash stock compensation to our adjusted EBITDA. This is consistent with our peers and provides a more comparable view of profitability on a cash basis. It also aligns with the covenant calculations under our new debt agreement. In the first quarter, adjusted EBITDA and adjusted EBITDA margin were $36 million and 23%, respectively, reflecting the quarterly revenue profile. Adjusted gross margin was 52%, reflecting the fixed -- high fixed cost nature of our operations. We also maintained strong cost discipline. Operating expenses were $57 million in the first quarter of 2026, down $10 million year-over-year, and R&D spend declined by about 1/3 compared to the first quarter of 2025.

Total revenue was $156 million, supported by a solid contribution from naloxone as we continue to maintain a market leadership position. The MCM portfolio performed above our expectations, driven by U.S. government order timing and shipments. International MCM revenue was 37% of total MCM revenues in the quarter, representing continued strong demand and diversification beyond the U.S. government. On Slide 16, we highlight the sustained improvements across our quarterly financial metrics. Liquidity and cash both improved by $11 million year-over-year, and we reduced net debt by $122 million or approximately 22% versus the first quarter of 2025.

As a result, we continue to see improvement in our net leverage ratio, which was 2.4x adjusted EBITDA at 1Q '26 versus 2.7x at the first quarter of '25. This level gives us meaningful financial flexibility as we evaluate capital allocation priorities to further strengthen our long-term growth profile. This observation provides a good segue to our April 2026 debt refinancing transaction, which is highlighted on Slide 16. Also noted there, we decreased our total term loan debt by $100 million versus the first quarter of 2025. And we increased finance capacity with the addition of a new fully committed delayed draw term loan of $75 million.

As Joe noted earlier, the April 2026 debt refinancing was an important milestone for Emergent. First, it strengthens our ability to preserve liquidity to support ongoing operations and advance long-term strategic initiatives. Second, it lowers our interest expense, freeing cash flow that can be redeployed into value-creating investments that support growth. Finally, it meaningfully extends our maturity profile and improves covenant terms. Taken together, these actions help establish a stronger financial foundation to support durable long-term growth. Turning to capital allocation. We have several strategic growth priorities in place for 2026, growing international MCM, internal R&D investments and business development. Continued debt management will remain an important part of our turnaround in 2026.

As noted, the April 2026 refinancing provides us with meaningfully greater financial flexibility and supports our long-term strategic growth plan. As a reminder, we have a $50 million share repurchase program through March 31, 2027, and we continue to utilize it, repurchasing 900,000 shares for $9 million during the first quarter of 2026. As of the end of the first quarter, $46.5 million of authorized repurchase capacity remains available under this program. At current valuation levels, we believe disciplined repurchases can be an attractive way to create shareholder value, and they reflect our confidence in Emergent's long-term prospects. One final note on our March 31 balance sheet.

We previously disclosed that $50.4 million of contingent consideration could be owed to Ridgeback Bio in the second quarter of this year, assuming continued progress under our contract with BARDA. As we now expect those conditions will be met, we have reported that amount as an accrued acquisition obligation under current liabilities. On Slide 19, we highlight our revenue and profitability guidance. We are maintaining our full year total revenue guidance of $720 million to $760 million. Commercial revenues are expected to be flat to slightly up with volume offsetting anticipated price adjustments, and we expect NARCAN to maintain its leading market share.

MCM revenues are consistent with prior guidance of flat to slightly down with a significant contribution from international sales. Adjusted gross margin is expected to be between 45% and 47%, reflecting product mix and expected pricing dynamics. We are updating our adjusted EBITDA guidance to account for the non-cash stock compensation add-back, and we, therefore, expect full year adjusted EBITDA to be in the range of $155 million to $175 million. And for the second quarter, we expect total revenue to be between $170 million and $185 million. In summary, we have fully commenced the turnaround phase of our multiyear plan, and we are executing with focus and urgency.

We delivered solid revenue and profitability in the first quarter, in line with our internal expectations. Our term loan refinancing extended maturities out to 2031 and enhanced our financial and operational flexibility. We also returned capital to shareholders through share repurchases during the quarter and $46.5 million of authorized repurchase capacity remained available through March of 2027. And with that, I'd like to turn the call back over to Joe for a 2026 business outlook update and closing remarks before we go into Q&A. Joe?

Joseph Papa: Thanks, Rich. Moving to Slide 21. Let me now walk through what we see as the key growth drivers we have, both near term and strategic. We entered 2026 with a stronger cash and liquidity position, further reinforced by the April refinancing. We are well positioned to invest in sustainable long-term growth via four levers: organic growth through internal R&D investments in TEMBEXA, Ebanga, and Raxibacumab; number two, line extensions for NARCAN; number three, growing the MCM business internationally; and number four, accelerating business development opportunities like projects such as KLOXXADO, like now we just announced the Japanese encephalitis vaccine and more for the future. Moving to our pipeline assets on Slide 22.

TEMBEXA, Ebanga, and Raxibacumab are all approved with incremental development programs underway. As I previously mentioned, we look forward to serving as the distributor of the Substipharm Biologics Japanese encephalitis vaccine for the U.S. government opportunity following FDA regulatory approval. Finally, we're pleased to share that just this week, ACAM2000 received Singapore Health Sciences Authority expanded approval to include PO. On Slide 23, to close, Q1 2026 has been a steady and successful continuation of the turnaround efforts in these past two years. We believe we have made significant headway and now have the opportunity to pursue growth both organically and inorganically. We have successfully stabilized the business. We have divested non-core assets.

We have dramatically reduced our debt while returning capital to shareholders. Today, we are investing for segment revenue growth, investing in promising internal R&D pipeline, expanding our international MCM footprint and pursuing accretive external opportunities all through a position of improved financial strength. All the while, we are committed to patient safety, quality and compliance across the operations. With that, operator, please open the line for questions.

Operator: [Operator Instructions] Your first question comes from the line of Jessica Fye with JPMorgan.

Jessica Fye: I had a question on your longer-term perspective on the naloxone franchise. I know you talked about that business being like flat to slightly up for 2026. How should we think about it taking like a -- maybe like a several year time horizon?

Joseph Papa: Sure. Thanks for the question. The way we're looking at NARCAN is a couple of things that are happening. Number one, we're excited about our ability to launch new innovations with NARCAN. We do have just the launch opportunity that we have with the carrying case. We think that's perfect for college campuses. We also looked at the multipack. We think the multipack will be a more efficient way to deliver the naloxone NARCAN for especially high-volume users. We do think there's still some significant upside internationally, especially in Canada. And we're also looking at the Q2, Q3 as being an upside from where we are in Q1 simply because of the seasonality of our business.

We know that like, for example, Q2 is the fiscal year-end for about 70% of the states. So, we think there is some upside there in the near term. And so, there's always going to be a little bit of seasonality. Beyond that, though, clearly, getting to the longer-term part of your question, we do think the market is going to continue to grow because unfortunately, there's still so many deaths that are occurring because of opioid overdoses. So, we do expect to see continued dollar spent there by the federal government.

We saw that in 2026 budget for the U.S. government, the SOR grants and the other grants that are coming from the federal government has either increased or at least stayed stable. So, there's continued bipartisan support for this area of overcoming opioid overdoses. So we do expect that. And then on top of that, the other reason we expect the volume to go up is just simply the class action settlements by large pharma companies are about $50 billion all that, we think, especially now that Purdue just settled this week, I guess it was, with about $5 billion of their settlement funds coming in.

Those funds are to be directed towards things like educational programs of states and local municipalities and/or the use or purchase of procurement of naloxone. So, we think for those reasons, the market will grow. We expect to hold on to the leading market position. We're going to stay competitive on pricing. So, we can't exactly say where pricing is going to go. But that's the reason why we said for the full year, flat to up slightly, and that's how we're looking at the future. Volume growth, we'll continue to be market leader. And then obviously, we'll have to be competitive on price. And that's really how we've talked about the future.

Volume growth, hold market share and expect to be competitively priced, and that's how we're thinking. So thanks for the question.

Jessica Fye: Yes. And then maybe switching to the MCM business as you kind of drive the international side there. Can you just remind us how to think about the margin you keep on international MCM sales and kind of how that compares to the U.S. legacy MCM business?

Joseph Papa: Sure. Well, I'll start, Rich, you may want to add to it. I guess the first and foremost thing is that one of the things that we've agreed to, especially with the current administration is that we offer a most favored nation pricing type of arrangement to the U.S. government. So, our price has to be by agreement with the U.S. government. We have to give them the lowest price which means by definition, our prices for other countries around the world will be slightly higher, depending on the product, of course. So, we think that, obviously, as we develop more international business will help us as well on the gross margin.

As I said, this year, for the first quarter, about 37% of our MCM revenue came from international. So, we think that's a big powerful part of how we're thinking about what's happening on the margin side. But Rich, anything you want to add?

Richard Lindahl: Yes. I think logically, Jess, the fact that we're offering the U.S. most favored nation pricing, and therefore, we have higher prices on the international MCM business, that drives higher margins. And so, you should assume that the international sales are above the average for the MCM segment in total.

Joseph Papa: Operator, next question. Operator, are there any more questions?

Operator: Your next question comes from Raghuram Selvaraju with H.C. Wainwright.

Raghuram Selvaraju: Firstly, I wanted to ask about the tie-up with SAB and if we should be thinking about this as an indication of interest in the type 1 diabetes space strategically or if this is really more of a contractual business arrangement and not indicative of a broader strategic shift? Secondly, I was wondering if you could comment on the evolving geopolitical situation generally and how you see that potentially driving international demand for MCM products under the Emergent banner? And lastly, I was wondering if at this juncture, you could comment on the scope and footprint of the manufacturing operations at Emergent and if you feel that those are optimally rightsized for the company going forward?

Joseph Papa: Okay. I'm going to try to make sure I get all of them, but please remind me if I'm missing any, Ram. First, on SAB, we're delighted to partner. They're a great company. They have a specific area of focus on the diabetes side. What we're focused on really is our technology and the technology that we have in Winnipeg that is perfectly situated to help them to advance their product. So, we view it as very much an alignment of our capability and what we had in Winnipeg with what they're looking for.

And it was really -- it wasn't as much disease category as it was an alignment around our technology, what they are looking for and how we can quickly expedite their operations and their products. So, it was really more of a technology than it was a therapeutic area approach. The second question, I think, is really about the international and what's happening out there and what we refer to as increasingly dangerous world. And you know, you've seen it in your reports. It is a more dangerous world that we live in. And I think the world has very appropriately worried about the risk of nuclear weapons, and we hear about every day in the news.

But one of the things that we believe, and I think you might also believe is that while nuclear weapons are absolutely a terrible risk, the risk of bioterror is maybe as risky, if not worse, in the sense that nuclear weapons will be terrible, devastating to a location or whatever could happen. However, bioterrorism once it get started, it's very difficult to stop. So -- and it's perhaps even easier to do a bioterrorist activity in terms of the speed at which you can do it and the cost at which you can do it than it is nuclear weapons. So we believe it's a dangerous world.

We believe bioterrorism could -- once it gets started, it can be devastating to society. And that's why we think it's really important to continue to work with the U.S. government and other governments around the world to make sure that everyone is prepared for these types of risks as we think about the future because one bad actor gets their hands on anthrax spores or smallpox and the results can be devastating. So that's really -- we certainly think the world is more dangerous and what we have to be prepared for it. The last question on the manufacturing footprint. We've streamlined our footprint to be clear.

However, we still have the ability to source all of our products, our existing products and our ability to ramp up our Canton facility, we think is a great opportunity to bring some additional drug substance capabilities for very difficult products. We have the ability there to work with live virus and Category B live viruses there. So, bring drug substance capability and bring that capability into the U.S. And we look around the country to see who else has that kind of capabilities, not a lot of it. So, we think having some additional capabilities for the U.S. is important.

It's important for this particular product, but it's also going to be important for other development candidates and/or products that the U.S. government, BARDA, Strategic National Stockpile are looking for. So we do think expanding the footprint and bringing Canton back online with additional capacity and expansion is an absolutely worthwhile endeavor, and we're delighted to get started with that as we speak. I think I got three -- all three of them, but did I leave anything out, Frank? Okay, I'll take that as we got all of it. Operator, do we have any other questions?

Operator: Yes, we do. Your next question comes from the line of Rishi Parekh with JPMorgan.

Unknown Analyst: Most of my questions have been asked, but just out of curiosity, as you think about all the international opportunities that you're working on, is there any way to quantify what the backlog of those opportunities look like as they try to or attempt to leverage your technology? And how should we just think about that margin potential as you continue to ramp on that backlog?

Joseph Papa: Sure. So do we have ongoing discussions on international opportunities to bring additional products to the market on the MCM product? The answer is absolutely yes. Those are ongoing discussions. It's a little bit harder to answer the backlog question because some of those projects take six months, some two years. I mean there's a process that we get involved with. But there's no doubt there's incremental interest for some of our products. So for example, in Europe, there used to be another manufacturer of an anthrax vaccine. Our knowledge is that, that manufacturer is no longer operating. So anybody who is looking for an anthrax vaccine, in many ways, Emergent is a place to go for it.

So we do think there are some developing opportunities. We're working on continuing to reinforce those. And we're doing it not just in Europe, we're doing in the Middle East, we're doing in Asia. We're really trying to make sure that wherever the demand is, wherever countries look at this risk of bioterrorism, biodefense, we're going to be there with our products. And as I said earlier in the presentation, we have the leading portfolio of products, whether it's in smallpox, whether it be a vaccine for smallpox, therapeutic for smallpox, whether you need vaccine for anthrax or a therapeutic for anthrax, whether you need something for botulism, something for Ebola, we've got it.

So we're looking to continue to work with all those governments around the world in terms of making sure we have products that we're working through our backlog as we've answered before, anything that we sell outside the U.S., by definition, is going to have a higher price and therefore, a higher margin since the relative cost will be the same. So, we're excited what that means. And the fact that normally, our business on international for MCM historically has been in the mid-teens as a percentage of business. The fact now that we're operating in the first quarter at about 37%. I think last year was about 34% by recollection.

You can see that we're making good progress with this international expansion footprint that we put in place in 2024 and 2025.

Operator: Your next question comes from the line of Alex Kelsey with Wells Fargo.

Alex Kelsey: Rich, I think I missed it when you were talking about the accrued acquisition obligation. Can you just mention again what exactly that's related to? And then maybe more importantly, is that a cash outflow that we should expect in 2026?

Richard Lindahl: Yes. Thanks for the question, Alex. That relates to the Ebanga program. And so this is under our acquisition of the rights to Ebanga from Ridgeback Bio. Once we were awarded the BARDA contract back in 2023, we disclosed that part of that arrangement was ultimately a payment to Ridgeback Bio, assuming that we continue to make progress under the contract, and that's going to be a cash outflow in the second quarter.

Joseph Papa: Alex, thank you for the question. Operator, any additional questions?

Operator: And at this time, I'm showing no further questions. I would now like to turn it back to Joe Papa for closing remarks.

Joseph Papa: Thank you, operator. Thank you, everyone, for joining us on the call today. I'd like to thank all of our investors, customers and employees for your strong and continued support of our company, and we look forward to providing further updates throughout the year. Thank you, and have a great day, everyone. Thanks for joining us. Have a great day, everyone.

Operator: Yes. Thank you for your participation in today's conference. This does conclude the program, and you may now disconnect.